TMEM200B and cancer: Despite conflicting results regarding the relationship of the tTMB and ICI response in clinical trials [139,140], the determination of tTMB and the subsequent selection of patients for pembrolizumab treatment in advanced non-resectable or metastasized cancers, including NSCLC, was approved by the FDA in 2020 [141].